Related Experiment Video
Updated: Aug 14, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Tipranavir: a protease inhibitor for multi-drug resistant HIV-1
Brookie Best1, Richard Haubrich
1University of California, San Diego, CA 92103-8214, USA. brookie@ucsd.edu
Abstract:
Since the mid-1990s, combination therapies to treat HIV-1 infection have greatly reduced morbidity and mortality from AIDS in developed countries with access to the medications. However, the development of viral resistance to available antiretrovirals is one of the many limitations to therapy that has emerged. Of the 24 licensed antiretroviral medications and medication combinations in the US, tipranavir is one of the few agents to specifically target highly treatment-experienced patients with multi-drug resistant HIV-1. It displays activity against the virus that is cross-resistant to other protease inhibitors. In this review, issues in treating multi-drug resistant HIV-1 and the potential clinical utility of tipranavir in the US will be discussed.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Antiprotozoal Agents
Retroviruses

